Table 5.
Joint effects analysis of MCM2 and MCM6 expression in HCC patients OS
| Group | MCM2 | MCM6 | Patients | NO. of event | MST | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P § |
|---|---|---|---|---|---|---|---|---|---|
| GSE14520 cohort | n=212 | months | |||||||
| A | High | High | 86 | 39 | 53 | 1 | 1 | ||
| B | High | Low | 20 | 9 | NA | 0.874(0.423-1.805) | 0.716 | 0.803(0.384-1.679) | 0.56 |
| C | low | High | 20 | 8 | NA | 0.747(0.349-1.598) | 0.452 | 0.791(0.365-1.714) | 0.552 |
| D | Low | Low | 86 | 26 | NA | 0.537(0.327-0.883) | 0.014 | 0.562(0.339-0.929) | 0.025 |
| TCGA cohort | n=370 | days | |||||||
| a | High | High | 153 | 69 | 1005 | 1 | 1 | ||
| b | High | Low | 32 | 7 | 2542 | 0.393(0.181-0.857) | 0.019 | 0.444(0.202-0.977) | 0.044 |
| c | low | High | 32 | 7 | NA | 0.431(0.198-0.938) | 0.034 | 0.442(0.190-1.028) | 0.058 |
| d | Low | Low | 153 | 47 | 2116 | 0.502(0.346-0.728) | <0.001 | 0.584(0.388-0.881) | 0.01 |
Notes: § Adjusted for tumor size, cirrhosis, BCLC stage in GSE14520 cohort; and adjusted for tumor stage and radical resection in TCGA cohort. MCM, minichromosome maintenance; HCC, hepatocellular carcinoma; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval; TCGA, The Cancer Genome Atlas; NA, not available.